Home >  Medicine MDTV >  Medicine Shorts >  Clinical Trial Shows New...

Clinical Trial Shows New Tablet Safe and More Effective for Elimination of Intestinal Worms

By - Dr. Bhumika Maikhuri
Published On 2025-01-14 03:15 GMT   |   Update On 2025-01-14 09:12 GMT
Advertisement
A new tablet combining albendazole and ivermectin is safe and more effective than albendazole alone in treating Trichuris trichiura and other soil-transmitted helminths (STH), according to a clinical trial conducted by the STOP consortium. The findings, published in The Lancet Infectious Diseases, open opportunities to improve the control of these neglected tropical infections, which affect around 1.5 billion people worldwide.
“This fixed-dose co-formulation (FDC) has several advantages. It is easy to administer, as it is one single pill and does not require dose adjustments based on the child’s weight,” explains project leader Jose Muñoz, ISGlobal researcher and Head of the International Health Service at Hospital Clinic Barcelona. “Also, we hope that combining two drugs with different mechanisms of action will reduce the risk of the parasites becoming drug-resistant,” he adds.
Advertisement
The ALIVE clinical trial tested the safety and efficacy of the FDC in school-aged children infected with T. trichiura, hookworms, S. stercoralis or a combination. The children were randomly divided into three treatment groups: group 1 received a single dose of albendazole; group 2 received one dose of the FDC (FDCx1); and group 3 received three doses of the FDC (FDCx3) over three consecutive days.
Phase 2 of the trial focused on safety. A small number of participants were recruited and treated sequentially according to weight, to monitor any adverse effects caused by higher-than-usual doses of ivermectin (above 200 µg/ml). No serious adverse effects were observed, and side effects were similar to those in the albendazole group. This allowed the trial to proceed to phase 3, where efficacy was assessed in a much larger number of participants, alongside continued safety monitoring. Treatment efficacy was assessed based on cure rates (absence of eggs in stool samples post-treatment) and reduction in the number of eggs in stool compared to before the treatment. Although most infections were classified as light, both FDC regimens achieved higher egg reduction rates than albendazole alone.
Reference: Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial, Krolewiecki, AlejandroKrolewiecki, Alejandro et al. The Lancet Infectious Diseases, Volume 0, Issue 0
Full View
Tags:    
Article Source : The Lancet Infectious Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Bhumika Maikhuri

Dr Bhumika Maikhuri is an orthodontist with 2 years of clinical experience. She is also working as a medical writer and anchor at Medical Dialogues. She has completed her BDS from Dr D.Y. Patil Medical College and Hospital and MDS from Kalinga Institute of Dental Sciences. She has a few publications and patents to her credit. Her diverse background in clinical dentistry and academic research uniquely positions her to contribute meaningfully to our team.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

WHO Advises Against Routine Antibiotic Use in COVID-19 Cases Without Bacterial Infection

The Prediabetes Show - Episode 1: Reversing Prediabetes - Myth or Fact?

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Rectal Cancer - Dr. Poulami Basu

Dapagliflozin Reduces Heart Failure Risk After TAVI: Key Findings from the DapaTAVI Trial

Shedding Weight, Losing Muscle: Study Links GLP-1 Drugs to Reduced Muscle Mass

New Tool Can Calculate Heart Age and Reveal Hidden Cardiovascular Risks: JAMA

Study Reveals Artificial Sweetener May Weaken Cancer Immunotherapy

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds